Morgan Stanley’s Park Ha Biological Technology Co BYAH Stock Holding History

Morgan Stanley’s Portfolio BYAH Stock Details BYAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.3K	Buy	3,127 +3,125	+156,250%	+$30.2K	﹤0.01%	6733
2026 Q1	$17	Sell	2 -14	-88%	-$437	﹤0.01%	8183
2025 Q4	$996	Buy	16 +1	+7%	+$121	﹤0.01%	7367
2025 Q3	$2.93K	Sell	15 -3	-17%	-$3.73K	﹤0.01%	7221
2025 Q2	$256K	Buy	+18	New	+$121K	﹤0.01%	5754

Other funds holding BYAH

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Morgan Stanley's BYAH Position: Q2 2026 in Review

Morgan Stanley increased its Park Ha Biological Technology Co (BYAH) stake by 156,250% in Q2 2026, buying an estimated $30.2K and bringing the position to 3,127 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6733.

Morgan Stanley first reported a position in BYAH in Q2 2025 and has held it in 5 quarters since. The position peaked at $256K in Q2 2025. 2 funds tracked by Wall St. Rank hold BYAH as of Q2 2026.

Morgan Stanley held 3,127 shares of Park Ha Biological Technology Co worth $25.3K as of Q2 2026.
Morgan Stanley bought 3,125 Park Ha Biological Technology Co shares in Q2 2026, an estimated $30.2K.
Park Ha Biological Technology Co made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6733 holding.
Morgan Stanley first reported a position in Park Ha Biological Technology Co in Q2 2025 and has held it in 5 quarters since.
Morgan Stanley's Park Ha Biological Technology Co position peaked at $256K in Q2 2025.
2 funds tracked by Wall St. Rank held Park Ha Biological Technology Co as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.